Memorandum – MolePath #33

To: UNC Health Attending Physicians, House Staff, Nursing Coordinators, Department Heads and Supervisors

From: Karen Weck MD
Director, Molecular Genetics Laboratory

Jason Merker, MD, PhD
Director, Molecular Oncology

Herbert C. Whinna MD, PhD
Medical Director, McLendon Clinical Laboratories

Date: February 25, 2020

Subject: **Method change for *IDH1* and *IDH2* Mutation Testing**

Effective March 1st, the methodology for detection of the *IDH1* and *IDH2* mutations will be changing from Pyrosequencing to Sanger Sequencing.

This assay has been validated to detect the most relevant mutations of *IDH1* (codon 132 in exon 4) and *IDH2 (*codon 172 in exon 4) in gliomas and hematologic malignancies.

Specimen Requirements
Acceptable specimen type remains unchanged for this new method. Formalin-fixed paraffin-embedded tissue is preferred for solid tumor analysis, and fresh blood or marrow is preferred for hematologic malignancies. Due to the limit of detection of Sanger sequencing analysis, at least 50% tumor involvement in the relevant sample is required for testing.

Turn-around time
The turn-around time of testing is two weeks.

Test Order (EAP) number in EPIC
LAB67801 – *IDH1* and *IDH*2 Mutation Testing

LAB67891- Glioma Mutation Panel (includes *IDH1, IDH2* and *TERT* Promoter Mutation Analysis)

If you have questions, please call the UNC Molecular Genetics Lab at (984) 974-1825 or contact Dr. Jessica Booker at (984) 974-1456. E-mail: Jessica.Booker@unchealth.unc.edu

Website, https://www.uncmedicalcenter.org/mclendon-clinical-laboratories/